This review summarizes the latest clinical progress in ICI-based therapies for ovarian cancer, evaluates current predictive biomarkers such as PD-L1 expression, TMB, and homologous recombination deficiency (HRD), and highlights the safety and toxicity profiles of immunotherapy. The gene discussed is CD274; the disease is ovarian cancer.